Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Review, H2 2014', provides an overview of the Familial Chylomicronemia (Type I Hyperlipoproteinemia)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Familial Chylomicronemia (Type I Hyperlipoproteinemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Familial Chylomicronemia (Type I Hyperlipoproteinemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Familial Chylomicronemia (Type I Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Overview 6 Therapeutics Development 7 Pipeline Products for Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Overview 7 Pipeline Products for Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Comparative Analysis 8 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Therapeutics under Development by Companies 9 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Unknown Stage Products 12 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Products under Development by Companies 13 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Companies Involved in Therapeutics Development 14 Aegerion Pharmaceuticals, Inc. 14 Catabasis Pharmaceuticals, Inc. 15 Isis Pharmaceuticals, Inc. 16 Novartis AG 17 uniQure N.V. 18 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 alipogene tiparvovec - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CAT-2003 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ISIS-APOCIIIRx - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 lomitapide mesylate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 pradigastat sodium - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Recent Pipeline Updates 35 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Product Development Milestones 48 Featured News & Press Releases 48 Dec 03, 2014: ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine 48 Aug 28, 2014: Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS 49 May 02, 2014: Catabasis Demonstrates CAT-2003 Lowers Fed and Fasting Triglycerides in Studies Presented at Lipid Conferences 50 May 02, 2014: Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With Familial Chylomicronemia 51 Apr 25, 2014: Catabasis to Present CAT-2003 Data at Upcoming Lipid Conferences 52 Mar 31, 2014: Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates 53 Mar 17, 2014: uniQure and Chiesi Announce Six Year Follow-up Data from Glybera Treated Patients 54 Jan 13, 2014: Isis Announces Positive Decision On European Orphan Drug Designation For ISIS-APOCIII Rx 55 Nov 18, 2013: Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels 56 Sep 22, 2013: Isis Pharmaceuticals to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 59 Disclaimer 59
List of Tables Number of Products under Development for Familial Chylomicronemia (Type I Hyperlipoproteinemia), H2 2014 7 Number of Products under Development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Unknown Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2014 14 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 15 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 16 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by Novartis AG, H2 2014 17 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by uniQure N.V., H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics - Recent Pipeline Updates, H2 2014 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.